Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

MeSH terms

• Fusion Proteins, bcr-abl* / antagonists & inhibitors
• Fusion Proteins, bcr-abl* / genetics
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
• Proto-Oncogene Proteins c-abl / antagonists & inhibitors
• Proto-Oncogene Proteins c-abl / genetics
• Tyrosine Kinase Inhibitors* / therapeutic use